Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-12-23

FDA Approved: SAVELLA — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Savella (milnacipran hydrochloride) submitted by Allergan, resulting in a labeling change for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SAVELLA (milnacipran hydrochloride)

Snippet

SUPPL AP for SAVELLA (MILNACIPRAN HYDROCHLORIDE)